Z17.420
Hormone receptor negative with human epidermal growth factor receptor 2 positive status
Clinical Classification Guidelines
Inclusion Terms
- HR- with HER2+
Medical Intelligence & Overview
The medical code Z17.420 refers to a specific cancer classification where the tumor lacks hormone receptors but tests positive for human epidermal growth factor receptor 2 (HER2). This profile usually applies to breast cancer cases and influences treatment options and prognosis. Hormone receptor negative means the cancer cells do not have estrogen or progesterone receptors, whereas HER2-positive indicates an overexpression of the HER2 protein, which can promote the growth of cancer cells.
Causes & Symptoms
Clinical Causes: Genetic mutations that lead to abnormal protein expression on the surface of breast cells. Hereditary factors increasing the likelihood of specific cancer subtypes. Environmental or lifestyle influences, though exact causes are not fully understood. Previous exposure to radiation or certain chemical agents. Mutations in genes such as TP53 or BRCA1/2 may contribute to the development of this cancer profile.
Key Symptoms: Lump or mass in the breast that may be painless or tender. Changes in the size, shape, or appearance of the breast. Skin changes such as redness or dimpling over the affected area. Nipple abnormalities, including inversion or discharge. Unexplained pain in the breast or nipple area. Swelling or a lump under the arm indicating possible lymph node involvement.
Diagnostic & Treatment
Diagnosis Path: Diagnosing hormone receptor negative and HER2-positive breast cancer involves several steps: - **Imaging Tests:** Mammograms, ultrasounds, or MRI scans to detect and evaluate the size and location of the tumor. - **Biopsy:** Removal of tissue sample for microscopic examination to determine receptor status. - **Receptor Testing:** Laboratory analysis to assess hormone receptor and HER2 status using immunohistochemistry or fluorescence in situ hybridization (FISH). - **Additional Tests:** Depending on the case, further tests such as CT scans or bone scans may be performed to check for spread. This comprehensive diagnosis helps in confirming the subtype and guiding treatment planning.
Treatment Protocols: Treatment strategies for hormone receptor negative and HER2-positive breast cancer are tailored based on the tumor profile and extent of the disease. Common approaches include: - **Targeted Therapy:** Medications such as trastuzumab (Herceptin) or pertuzumab that specifically target HER2 proteins to inhibit tumor growth. - **Chemotherapy:** Often administered to destroy cancer cells; may be used before or after surgery. - **Surgery:** Procedures such as lumpectomy or mastectomy to remove the tumor. - **Radiation Therapy:** Used post-surgery to eliminate residual cancer cells, reducing recurrence risk. - **Supportive Care:** Includes hormonal therapies are generally ineffective in this subtype and are replaced with targeted agents. Multidisciplinary teams develop personalized treatment plans aimed at maximizing effectiveness while managing potential side effects.
Clinical Advice & FAQs
Billing Guidance
Is Z17.420 a billable ICD-10 code?
Yes, Z17.420 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report Z17.420?
Clinical documentation must specify the nature of Hormone receptor negative with human epidermal growth factor receptor 2 positive status and any associated comorbidities for accurate reporting.
Cite this Clinical Reference